Search | Engineering

Subscribe Submit

Home Journals Focus Achievement Fronts About Us 中文版

Resource Type

Journal Article 3

Year

2021 1

2019 1

Keywords

tocilizumab 3

cytokine storm 2

COVID-19 1

SARS-CoV-2 1

chimeric antigen receptor T cell 1

coronavirus disease 2019 (COVID-19) 1

cytokine release syndrome 1

interleukin-6 1

open ︾

Search scope:

排序： Display mode:

Cytokine storm and translating IL-6 biology into effective treatments for COVID-19

Frontiers of Medicine doi: 10.1007/s11684-023-1044-4

Abstract: cytokine storm and the process of targeting IL-6 signaling to elucidate the pivotal role played by tocilizumab

Keywords： SARS-CoV-2 COVID-19 cytokine storm interleukin-6 tocilizumab

HTML PDF Collect

Tocilizumab in patients with moderate or severe COVID-19: a randomized, controlled, open-label, multicenter

Dongsheng Wang, Binqing Fu, Zhen Peng, Dongliang Yang, Mingfeng Han, Min Li, Yun Yang, Tianjun Yang, Liangye Sun, Wei Li, Wei Shi, Xin Yao, Yan Ma, Fei Xu, Xiaojing Wang, Jun Chen, Daqing Xia, Yubei Sun, Lin Dong, Jumei Wang, Xiaoyu Zhu, Min Zhang, Yonggang Zhou, Aijun Pan, Xiaowen Hu, Xiaodong Mei, Haiming Wei, Xiaoling Xu

Frontiers of Medicine 2021, Volume 15, Issue 3, Pages 486-494 doi: 10.1007/s11684-020-0824-3

Abstract: Tocilizumab has been reported to attenuate the “cytokine storm” in COVID-19 patients.We attempted to verify the effectiveness and safety of tocilizumab therapy in COVID-19 and identify patientsThe patients were randomly assigned in a 1:1 ratio to receive either tocilizumab in addition to standardThirty-three patients were randomized to the tocilizumab group, and 32 patients to the control group.The cure rate in the tocilizumab group was higher than that in the control group, but the difference

Keywords： tocilizumab coronavirus disease 2019 (COVID-19) cytokine storm

HTML PDF Collect

Management of cytokine release syndrome related to CAR-T cell therapy

Hongli Chen, Fangxia Wang, Pengyu Zhang, Yilin Zhang, Yinxia Chen, Xiaohu Fan, Xingmei Cao, Jie Liu, Yun Yang, Baiyan Wang, Bo Lei, Liufang Gu, Ju Bai, Lili Wei, Ruili Zhang, Qiuchuan Zhuang, Wanggang Zhang, Wanhong Zhao, Aili He

Frontiers of Medicine 2019, Volume 13, Issue 5, Pages 610-617 doi: 10.1007/s11684-019-0714-8

Abstract: The early application of tocilizumab, an anti-IL-6 receptor antibody, according to toxicity grading andMoreover, low doses of dexamethasone (5–10 mg/day) were used for refractory CRS not responding to tocilizumab

Keywords： chimeric antigen receptor T cell cytokine release syndrome tocilizumab